Codexis outfits CDMO with biocatalyst tech in new partnership model

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/daizuoxin)
(Image: Getty/daizuoxin)
Codexis is setting up Porton Pharma Solutions with its biocatalyst technology as part of a strategic collaboration aimed at liberating potential cost reductions of up to 20%, says CEO.

Codexis’​ proprietary CodeEvolver technology develops proteins for various applications, including as biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals, and for use as industrial enzymes, according to the company.

Per the strategic collaboration with Porton​, Codexis will license elements of its biocatalyst technologies to the China-headquartered contract development and manufacturing organization (CDMO).

Additionally, Porton has made a commitment to invest in new operations with the goal of driving adoption of the technologies into its CDMO offerings.

“We’re setting up Porton to be a frontline for us in the world of small- to medium-sized pharmaceutical companies,”​ said John Nicols, Codexis president and CEO at CPhI North America last month.

The partnership aims to accelerate the creation and commercialization of new manufacturing processes.

“When we get the catalyst efficiency right we’ll liberate 10 to 20% cost reductions versus any other way to build that molecule,”​ Nicols told us at the event. “Then we create this cost reduction that then can benefit Codexis, Porton, and the ultimate pharmaceutical company.”

Partnership model

Nicols said the company has been trying to figure out how to effectively work with CMOs for years, without much success. “So it took a progressive company like Porton and it took a new model that we created and introduced for this deal,”​ he explained.

“They put significant commitment into this on the belief and expectation that it will lead to low-cost processes,”​ he added. As such, Nicols said Codexis will not be offering the technology to other CMOs under the same model.

Looking forward, if Codexis announces that Porton is building an enzyme manufacturing plant, Nicols said “that will be a sign that this model is really working.”

Though any such potential news is not to be expected until a “couple years out,” ​he added.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us